New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 30, 2014
07:09 EDTFLMLFlamel Technologies announces FDA approval of Vazculep
Flamel Technologies announced that the FDA has approved the company's New Drug Application, or NDA, for Vazculep. Vazculep Injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Flamel expects to launch Vazculep in the next few months in 1 mL single use vials, and 5 mL and 10 mL pharmacy bulk package vials. The drug strength is the same in all vials at 10 mg/mL. Phenylephrine hydrochloride is used in operating rooms and is injected intravenously either as a bolus or in a dilute solution as a continuous infusion.
News For FLML From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
07:56 EDTFLMLFlamel backs FY15 revenue guidance of $170M-$185M, consensus $194.87M
Subscribe for More Information
07:56 EDTFLMLFlamel reports Q2 adjusted EPS 34c, consensus 40c
Subscribe for More Information
July 22, 2015
08:31 EDTFLMLFlamel to begin U.S. public company reporting status in FY16
Flamel announced that as of June 30, it has determined that it no longer satisfies the definition of a "foreign private issuer" under the rules and regulations of the SEC. The company made the determination based on the fact that the proportion of its voting securities currently held by U.S residents is approximately 80% or greater and a majority of its executive officers are U.S. citizens or residents. As a result, beginning on January 1, 2016, the company will be filing Annual Reports on Form 10-K, commencing with the annual report to be filed for the year ended December 31, 2015, Current Reports on Form 8-K, Quarterly Reports on Form 10-Q as well as proxy statements with respect to meetings of shareholders, with the SEC as if it were a fully domestic U.S. company.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use